Cocaine Use in Ireland: an Exploratory Study
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Methamphetamine & Opioid Response Initiative
Billings Metro VISTA Project Methamphetamine & Opioid Response Initiative: A Community Assessment July 2019 AmeriCorps VISTAs: Nick Fonte and Amy Trad Table of Contents EXECUTIVE SUMMARY ......................................................................................................................................... 3 INTRODUCTION ....................................................................................................................................................... 4 Section 1: Area of Study ............................................................................................................................................ 4 Section 2: Methamphetamine vs. Opioids ................................................................................................................. 5 KEY STAKEHOLDERS ............................................................................................................................................ 6 Section 1: Community Organizations/Non-profits .................................................................................................... 6 Section 2: Statewide and Local Initiatives ................................................................................................................ 9 RELEVANT DATA ................................................................................................................................................... 11 Section 1: Methamphetamine and Opioids in the News ......................................................................................... -
Getting Through Amphetamine Withdrawal – a Guide for People
Amphetamine_wdl_220404.qxd 28/04/2004 12:19 PM Page i GETTING THROUGH AMPHETAMINE WITHDRAWAL A guide for people trying to stop amphetamine use Amphetamine_wdl_220404.qxd 28/04/2004 12:19 PM Page ii GETTING THROUGH AMPHETAMINE WITHDRAWAL CONTENTS About this book x Making the decision to stop using amphetamines x Amphetamine withdrawal x What is withdrawal? x How long will the symptoms last? What kinds of symptoms will I have? x Getting started x Organise a safe environment x Organise support x Structure your day x The role of medication x Getting through withdrawal x Cravings x Sleep x September 1996 Relaxing x Revised May 2004 Mood swings x © Turning Point Alcohol and Drug Centre Inc. Strange thoughts x 54-62 Gertrude Street, Fitzroy VIC 3065 Eating again x T: 03 8413 8413 Aches and pains x F: 03 9416 3420 High-risk situations x Counselling x E: [email protected] It’s all too much x www.turningpoint.org.au Sex and withdrawal x Original edition by Dr Nik Lintzeris, Dr Adrian Dunlop and After withdrawal x David Thornton What next? x Updated (2004) by Dr Adrian Dunlop, Sandra Hocking, Dr Getting back on track if you ‘slip up’ x Nicole Lee and Peter Muhleisen Notes for supporters x Cartoonist: Mal Doreian Useful contact numbers x ISBN 0_958 6979_1_4 1 Amphetamine_wdl_220404.qxd 28/04/2004 12:19 PM Page 2 GETTING THROUGH AMPHETAMINE WITHDRAWAL MAKING THE DECISION TO STOP USING AMPHEATMINES ABOUT THIS BOOK This book is written for people who are thinking about You may find it helpful to make a list of the positives and the or trying to stop using amphetamines, even if just for a negatives about using amphetamines. -
Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved. -
Identification and Brief Treatment Approaches for Substance Use Disorders the Care Transitions Network
Identification and Brief Treatment Approaches for Substance Use Disorders The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office of Mental Health Netsmart Technologies Presenters Dr. George C. Nitzburg, Research Scientist Dr. Nehal P. Vadhan, Assistant Investigator Center for Addiction Services and Personalized Interventions Research (CASPIR), Departments of Psychiatry and Molecular Medicine Hofstra Northwell School of Medicine Feinstein Institute for Medical Research Objectives • At the completion of this webinar, attendees will be able to: 1. Identify the characteristics of patients who are misusing substances, including alcohol, cannabis, and opioids 2. Know how to assess for substance use disorders, including differential diagnosis from bipolar and schizophrenia and recognizing co-occurring disorders 3. Describe treatment approaches substance use disorders, including alcohol, cannabis, and opioids What is your role? What is your primary role in your organization? A. Administrator B. Prescribing Clinician C. Non-prescribing clinician D. Researcher E. Other Outline • Overview of substance use • Identification of substance use disorders (SUD) • Treating SUDs • Alcohol • Cannabis (natural and synthetic) • Opiates Overview: Understanding Substance Use • Why use drugs? • Well-liked, and with few exceptions, we all use them (e.g., aspirin, caffeine) • Which drugs, and how much (e.g., alcohol), is what makes all the difference • Drugs induce positive feeling states -
MDMA / Ecstasy
What is MDMA/ Catch22 Surrey Young Peoples Substance Ecstasy? Misuse Service (Molly, Mandy, Pills , XTC, Beans, Doves) Catch22 Surrey Young People’s Substance Misuse service is a service for young people aged MDMA / MDMA is the official chemical name for the pure between 11 and 25 chemical compound. 3,4-Methylenedioxy We offer free confidential advice and support. methamphetamine or more commonly known as Ecstasy Ecstasy (E), it is a psychoactive drug. If you would like to know more about the risks and effects of alcohol or drugs, or are struggling Understanding the risks MDMA/Ecstasy is a "psychedelic" stimulant drug and would like some help- we will listen and help usually sold as tablets, but is sometimes dabbed on to you work through your problems. gums or snorted in its powder form. Please contact There is no safe level of drug use. It is MDMA/Ecstasy is a drug that is used recreationally important to be careful when taking any because of the way it can make people feel euphoric 24/7 helpline 08006226662 type of drug. and empathetic. Users may take it to feel energised, T: 01372 832905 happy or to stay awake and dance for hours. The Text: 07595088388 effects take about half an hour to kick in and tend to Email: [email protected] last between 3 to 6 hours, followed by a gradual Facebook & Twitter: Catch22 YPSM comedown. catch-22.org.uk/surrey-substance-misuse Ecstasy is often taken at music festivals (often multi- Drug information for young people http://www.talktofrank.com/news/dangers- day events with multiple artists), nightclubs, raves xanax-misuse (large dance parties), or house parties. -
Drugwatch AMT Factsheet
48 factsheet Dosage: may feel an energy drain, low mood Oral Smoked or experience flu-like symptoms and Threshold 5-15mg Threshold 2mg AMT general tiredness/lethargy. This typically Light 10-20mg Light 4-5mg happens a day or two after use, which Common 20-40mg Common 6-10mg some users call the “Tuesday blues”. Strong 40-60mg Strong 10-20mg Some anecdotal reports suggest AMT has Heavy 60-100mg Drug overview: less of a hangover than drugs such as Alpha-methyltryptamine (MT/AMT) MDMA although this is not an indication Pellets are reported to contain a dosage is a currently legal new psychoactive of long term safety. of 30mg. substance. It is a long acting, synthetic Patterns of use: psychedelic. Typical effects and side effects Patterns of use appear to be similar to These are some of the typical effects and Background: drugs such as LSD. There seems to be side effects experienced by people who AMT was originally developed as an little tendency to re-dose quickly unless a use AMT, not everyone will experience antidepressant in the 1960s by the user believes they have not taken enough all effects listed and many can be dose company UpJohn. In the 1990s AMT to experience full effects. dependent. resurfaced as a drug of recreational use Long term effects/known harms: made available over the internet. It was Physical: Mental: AMT is a relatively unknown substance first seen in the UK in February 2011. • Increase in • Mood and little is known about the long- energy enhancement Appearance: term effects and potential harms. -
Borders Alcohol & Drugs Partnership (ADP)
Borders Alcohol & Drugs Partnership (ADP) Drug Briefing: Alprazolam (Xanax) April 2018 Alprazolam is a benzodiazepine and is a class C controlled drug. It is not prescribed under NHS but its availability is increased through illegal supply via online sources. Appearance: Alprazolam is most commonly seen in 1mg tablet form and 2mg bars more commonly known as Xanax but is also available in powder form which can be mixed with other substances. Strength: Alprazolam is 20 times the potency of Diazepam and approximately twice as potent as Etizolam. Xanax tablets are active from 0.25mg (meaning 8 doses in a 2mg bar) so people consuming full tablets are taking a very large dose. If larger amounts of Xanax is consumed this can increase the risk of overdose especially if mixed with alcohol and other drugs. Cost: Across the UK street prices are estimated at £1.50 for 1mg and £3-5 for a 2mg Xanax bar, but this can vary and the more tablets purchased the cheaper the price. Across the UK the drug is being used either as a comedown aid from stimulants or psychedelics or to enhance dissociative effects of some drugs. Effects: Reported effects of pleasure, relaxation and bodily comfort, disinhibition and reduction in anxiety. Other effects may include: • drowsiness, feeling tired; • slurred speech, lack of balance or coordination; • memory problems; or • feeling anxious early in the morning. After effects include increase in hostility and aggression. This is not a complete list of side effects and others may occur. Harm reduction advice for individuals: • Wherever possible, do not use on your own • Alprazolam is 20 times the potency of diazepam. -
Syllabus and Proceedings Advances in Medicine Each Year in Medical Treatment and Lost Productivity
Syllabus and Proceedings Advances in Medicine each year in medical treatment and lost productivity. Further, as the public health crisis of prescription Saturday, May 20, 2017 drug abuse continues to grip the nation, the need to understand the biology of pain and the risks and Medical Mysteries and Practical Med Psych benefits of various pain treatments becomes critical. Updates: Is It “Medical,” “Psychiatric” or a Little of Despite these alarming concerns, few resources have Both...? been dedicated to study pain. Pain is the least Chair: Robert McCarron, D.O. studied phenomenon at the National Institutes of Presenters: Pritham Raj, M.D., Jeremy DeMartini, Health (NIH), yet the most common reason patients Glen Xiong, M.D., Matthew Reed, M.D. proceed to the emergency room seeking care. Moreover, many studies have documented EDUCATIONAL OBJECTIVE: substantial deficits regarding pain education in many 1) Better understand the interplay between general pre-licensure curricula in various health fields. medical conditions and abnormal or maladaptive Essential to the assessment of chronic pain is a behavior; 2) Discuss both common and less common detailed working knowledge of the biopsychosocial psychiatric presentations of frequently encountered model and the influence of mood on pain and vice general medical conditions; and 3) Review “up to versa. The following dynamic discussion will allow date” and evidence-based practice patterns for for a brief but important review of how pain figures medical/psychiatric conditions. into the model and the critical relationship between mood and pain. Next, we will address novel SUMMARY: therapies that address both mood and pain and dive Psychiatrists often encounter clinical scenarios that into the complex phenomenon of how we physically may not have a clear explanation. -
2018 National Drug Threat Assessment
UNCLASSIFIED//LAWUNCLASSIFIED ENFORCEMENT SENSITIVE UNCLASSIFIED UNCLASSIFIED//LAW ENFORCEMENT SENSITIVE UNCLASSIFIED This page intentionally left blank. UNCLASSIFIED UNCLASSIFIED Drug Enforcement Administration 2018 National Drug Threat Assessment This product was prepared by the DEA Strategic Intelligence Section. Comments and questions may be addressed to the Chief, Analysis and Production Section, at [email protected]. UNCLASSIFIED UNCLASSIFIED This page intentionally left blank. UNCLASSIFIED UNCLASSIFIED 2018 National Drug Threat Assessment TABLE OF CONTENTS Letter from the Acting Administrator ...............................................................................iii Executive Summary .............................................................................................................v Controlled Prescription Drugs ............................................................................................1 Heroin .................................................................................................................................11 Fentanyl and Other Synthetic Opioids .............................................................................21 Cocaine ...............................................................................................................................39 Methamphetamine .............................................................................................................59 Marijuana ............................................................................................................................77 -
Searchable Shulgin Pharmacology Notes, Book 9
The Shulgin Lab Books Pharmacology Lab Notes #9 (1986-1994) A Bit About This Document: While undertaking the work of investigating the chemistry and pharmacology of many varied psychoactive substances, Alexander “Sasha” Shulgin kept detailed notebooks. His documentation covered not only on his own personal research, but the research of friends and acquaintances. This book, the ninth of the “Pharmacology” series, represents mostly active dose work-ups of various substances. It covers the end of 1986 through half of 1994. The Creation of This Document: The project to undertake the transcribing of Shulgin’s Lab Books was started in 2008 by a team of volunteers and staff at Erowid, along with members of Team Shulgin. Various books were transcribed without a clear idea of how to present the information as a final product; eventually this format was chosen and a volunteer began work assembling the document. Each page was painstakingly transcribed from scanned images. All the hand-drawn “dirty pictures” (molecule drawings) and graphs were edited from the original scans and combined with drawn-in marks, outlines, and arrows to form this searchable PDF. Most of the names in this document have been redacted and pseudonyms put in their place. Names are presented as much as possible as they were in the original book, for example “Robert Thompson” is also “Robert”, “R.Thompson”, and “RT”. Initials are frequently used, and no two people share names or initials so the reader can keep track of who’s who. (ATS is Sasha and AP is Ann) Words highlighted in yellow are words that the transcription team could not decipher. -
National Report the Netherlands 2005 Final Version Version…
REPORT TO THE EMCDDA by the Reitox National Focal Point THE NETHERLANDS DRUG SITUATION 2005 FINAL VERSION REITOX REPORT ON THE DRUG SITUATION 2005 Margriet van Laar1 André van Gageldonk1 Toine Ketelaars1 Marianne van Ooyen2 Guus Cruts1 Esther Croes1 1Trimbos Institute, Netherlands Institute of Mental Health and Addiction 2WODC, Scientific Research and Documentation Centre, Ministry of Justice As approved on 06-02-2006 by the Scientific Committee of the NDM © NDM/Netherlands Focal Point 2005 Trimbos Institute NDM/Netherlands Focal Point PO Box 725 3500 AS Utrecht The Netherlands article number: AF0658 phone: +31-30-2971100 fax: +31-30-2971111 The Report on the Drug Situation in the Netherlands 2005 has been written for the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Each year, national centres of expertise on drug-related issues in the member states of the European Union (‘Focal Points’) draw up a report on the national drugs situation, according to guidelines provided by the EMCDDA. These reports form the basis of the “Annual Report on the State of the Drug Problem in the European Union” compiled by the EMCDDA. In line with the guidelines, the report focuses on new developments in the reporting year. This 2005 national report was written by the staff of the Bureau of the National Drug Monitor (NDM) at the Trimbos Institute and staff of the Scientific Research and Documentation Centre (WODC) of the Ministry of Justice. The NDM was established in 1999 on the initiative of the Ministry of Health, Welfare and Sports. The Ministry of Justice also participates in the NDM. -
Information Sheet Etizolam Version: 1.1 Original Version: 17/06/2014 Revision Date: 19/06/2014
Information Sheet Etizolam Version: 1.1 Original version: 17/06/2014 Revision date: 19/06/2014 Drug overview: Etizolam is a benzodiazepine analogue, a thienodiazepene1. It has gathered some popularity on the new psychoactive substance (NPS) market in the UK and Europe. Chemical name(s): 4-(2-chlorophenyl)-2-ethyl-9-methyl-6H- thieno[3,2- f][1,2,4]triazolo[4,3-a][1,4]diazepine2. Brand Names3: Etilaam, Etizest, Etizola, Sedekopan, Depas, Pasaden. Classification: Depressant. Background: Etizolam is unlicensed in the UK although used as a prescribed medication in other countries such as India4, Italy5 and Japan6. A 1mg tablet is equivalent to a 10mg Image: Wikimedia commons diazepam (Valium) tablet7. Appearance8: Etizolam typically comes in 1mg and 2mg tablets which are often described as ‘pellets’. Its appearance can vary depending on the source of purchase. A popular brand name Etilaam sold online is found in a foil strip packet with 1mg dark blue ‘sugar pill’-sized coated tablets. There are other tablets in circulation which are lighter blue (similar to blue diazepam colour) and can display the markings EZ9. The 2mg are often small dark pink coated tablets. Tablets from other vendors may simply come loose in a zip-seal plastic bag. It is also possible to purchase in powder form10, which is often white. Anecdotal reports suggest that it is rare for users to purchase the powder form in the UK. Cost11: Etizolam varies in cost, depending on the form and quantity purchased. They can range from £1 for single tablets (or in quantities less than 10), to as low as 5p per tablet at larger quantities.